SCHEMBL5568381

SCHEMBL5568381

CC(=O)c1[nH]c2ccccc2c1O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 10/20 0.53
ALDH1A1 P00352 5/20 0.53
MAPT P10636 4/20 0.53
IDE P14735 1/20 0.53
MPI P34949 1/20 0.53
CACNA1B Q00975 1/20 0.53
APBA1 Q02410 1/20 0.53
POLB P06746 2/20 0.53
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
DAO P14920 1/20 0.49
DDO Q99489 1/20 0.49
HPGD P15428 2/20 0.47
GAA P10253 1/20 0.47
GRIN2D O15399 1/20 0.46
GRIN3B O60391 1/20 0.46
GRIN1 Q05586 1/20 0.46
GRIN2A Q12879 1/20 0.46
GRIN2B Q13224 1/20 0.46
GRIN2C Q14957 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30373749 1.00 KDM4E (0.53) KDM4EALDH1A1MAPTIDEMPI
SCHEMBL28197191 0.84 ALDH1A1 (0.57) KDM4EALDH1A1MAPTIDEMPI
SCHEMBL30366683 0.82 KDM4E (0.62) KDM4EALDH1A1MAPTIDEMPI
SCHEMBL62193 0.82 KDM4E (0.62) KDM4EALDH1A1MAPTIDEMPI
SCHEMBL61857 0.81 MAP2 (0.62) KDM4EALDH1A1MAPTIDEMPI
SCHEMBL10704376 0.81 ALDH1A1 (0.61) KDM4EALDH1A1MAPTPOLBMEN1
SCHEMBL30572914 0.80 KDM4E (0.69) KDM4EALDH1A1MAPTMEN1KMT2A
SCHEMBL4207606 0.80 KDM4E (0.69) KDM4EALDH1A1MAPTMEN1KMT2A
SCHEMBL29150402 0.79 MAP2 (0.51) KDM4EALDH1A1POLBMEN1KMT2A
SCHEMBL1122596 0.79 ALDH1A1 (0.68) KDM4EALDH1A1MAPTIDEMPI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250236590-A1 A METHOD FOR THE PREPARATION OF INDOLE-3-CARBOXYLIC ACID DERIVATIVES DEB INDUBHUSAN 2025-07-24 US disclosed
CN-118265698-A Process for preparing indole-3-carboxylic acid derivatives 科学与工业研究会(按照印度社会团体注册法案(1860年第21号法案)设立的注册机构) 2024-06-28 CN disclosed
WO-2023067628-A1 A METHOD FOR THE PREPARATION OF INDOLE-3-CARBOXYLIC ACID DERIVATIVES COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN. OF SOC. ACT (ACT XXI OF 1860) (IN) 2023-04-27 WO disclosed
CN-105325466-B A kind of composition for inducing plant disease-resistant and coordinate plant growth, and its preparation method and application 沈阳化工研究院有限公司 2018-02-06 CN disclosed
CN-105325466-A Composition for inducing plants to resist diseases and adjusting plant growth and preparation method and application of composition SHENYANG RES INST CHEMICAL IND 2016-02-17 CN disclosed
EP-1751156-A1 6,7,8,9-SUBSTITUTED 1-PHENYL-1,5-DIHYDRO-PYRIDO(3,2-B)INDOL-2-ONES USEFUL AS ANTI-INFECTIVE PHARMACEUTICAL AGENTS Tibotec Pharmaceuticals Ltd. (IE) 2007-02-14 EP disclosed
EP-1750708-A1 COMBINATIONS OF SUBSTITUTED 1-PHENYL-1,5-DIHYDRO-PYRIDO- [3,2-B] INDOL-2-ONES AND OTHER HIV INHIBITORS Tibotec Pharmaceuticals Ltd. (IE) 2007-02-14 EP disclosed
WO-2005111035-A1 6,7,8,9-SUBSTITUTED 1-PHENYL-1,5-DIHYDRO-PYRIDO[3,2-B]INDOL-2-ONES USEFUL AS ANTI-INFECTIVE PHARMACEUTICAL AGENTS TIBOTEC PHARMACEUTICALS LTD. (IE) 2005-11-24 WO disclosed
WO-2005110411-A1 COMBINATIONS OF SUBSTITUTED 1-PHENYL-1,5-DIHYDRO-PYRIDO- [3,2-B] INDOL-2-ONES AND OTHER HIV INHIBITORS TIBOTEC PHARMACEUTICALS LTD. (IE) 2005-11-24 WO disclosed
EP-1594870-A1 SUBSTITUTED INDOLEPYRIDINIUM AS ANTI-INFECTIVE COMPOUNDS Tibotec Pharmaceuticals Ltd. (IE) 2005-11-16 EP disclosed
WO-2004046143-A1 SUBSTITUTED INDOLEPYRIDINIUM AS ANTI-INFECTIVE COMPOUNDS TIBOTEC PHARMACEUTICALS LTD. (IE) 2004-06-03 WO disclosed
US-5925647-A TREATMENT OF INSULIN NON-INSULIN DEPENDENT DIABETES SHAMAN PHARMACEUTICALS, INC. (US) 1999-07-20 US disclosed
US-5681958-A TREATMENT OF DIABETES SHAMAN PHARMACEUTICALS, INC. (US) 1997-10-28 US disclosed
WO-1996010015-A1 CRYPTOLEPINE ANALOGS WITH HYPOGLYCEMIC ACTIVITY SHAMAN PHARMACEUTICALS, INC. (US) 1996-04-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250236590-A1 A METHOD FOR THE PREPARATION OF INDOLE-3-CARBOXYLIC ACID DERIVATIVES IDO1, INMT, IDO2 KDM4E 2274/4885ALDH1A1 608/4885MAPT 1841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.